NED-260
Broad-spectrum antiviral
Pre-clinicalActive
Key Facts
About NED Biosystems
NED Biosystems is pioneering a novel systems-based therapeutic approach to treat complex diseases like cancer and viral infections by combining repurposed, oral drugs at non-toxic doses. Its lead asset, NED-170, is in development for cancer, while NED-260 is a platform-derived program aimed at being a universal antiviral. As a private, pre-revenue Public Benefit Corporation, the company is driven by a mission of global patient access and is led by founder/CEO Rebecca Lambert, supported by a seasoned team and scientific advisory board.
View full company profileTherapeutic Areas
Other Broad-spectrum antiviral Drugs
| Drug | Company | Phase |
|---|---|---|
| DDX3 Inhibitor (Antiviral) | Lead Discovery Siena | Preclinical |